American Century Companies Inc. Buys 246,645 Shares of Bioventus Inc. (NYSE:BVS)

American Century Companies Inc. raised its holdings in Bioventus Inc. (NYSE:BVS) by 38.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 884,673 shares of the company’s stock after buying an additional 246,645 shares during the quarter. American Century Companies Inc. owned 1.09% of Bioventus worth $9,289,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. HighTower Advisors LLC lifted its position in shares of Bioventus by 11.3% during the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock worth $143,000 after purchasing an additional 1,380 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock worth $202,000 after acquiring an additional 1,652 shares in the last quarter. Virtus Fund Advisers LLC acquired a new position in shares of Bioventus during the 3rd quarter worth about $42,000. Plato Investment Management Ltd acquired a new position in shares of Bioventus during the 4th quarter worth approximately $38,000. Finally, Quarry LP acquired a new stake in Bioventus in the third quarter valued at $59,000. Institutional investors own 62.94% of the company’s stock.

Insider Buying and Selling

In related news, CEO Robert E. Claypoole sold 28,786 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the completion of the sale, the chief executive officer now directly owns 64,964 shares in the company, valued at $591,172.40. This represents a 30.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Anthony D’adamio sold 4,380 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at $1,204,233.82. This represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,161 shares of company stock worth $436,364. Corporate insiders own 32.90% of the company’s stock.

Bioventus Stock Performance

Bioventus stock opened at $9.51 on Thursday. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a market capitalization of $779.29 million, a PE ratio of -15.59 and a beta of 0.86. The firm’s 50 day simple moving average is $10.02 and its 200 day simple moving average is $10.95.

Analyst Ratings Changes

Several equities research analysts have issued reports on BVS shares. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and upped their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.